Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.

GREY:TBPMQ - Post by User

Tetra Bio Pharma Inc > Why Mutual Funds & Institutional Investors Are Buying TBP

<< Previous

Bullboard Posts

Next >>

Comment by Golddetectoron Feb 05, 2022 8:05pm

121 Views

Post# 34401624

RE:Why Mutual Funds & Institutional Investors Are Buying TBP

Agreed. QIXLEEF is drug that went through years of development and research and it is at a very critical stage now at phase II of FDA the most advanced trial of pain medication against opioid. Phase II is proof of concept simply does work or not. Drug Safety already passed. The trial Is concluding in the next few weeks. It has been accelerated already. So what opioid alternative worth? Make a guess. That is why why I say Tbp with 10 to 20x of its current levels. Below the video from last presentation. Sorry the last post was not working. That is why imo QIXLEEF is more valuable than Reduvo even if Reduvo bring immediate revenue in 100m. QIXLEEF worth way more